Instil Bio Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Key Highlights
- ➤Cash position $67.1 million, expected to fund operations through 2027
- ➤Q3 net loss $4.2 million, down from $13.6 million year over year
- ➤Nine-month net loss $13.0 million, versus $63.5 million in 2025
- ➤R&D expense $0.2 million, down from $9.1 million year over year
- ➤Instil plans asset-focused subsidiaries and internally developed or in-licensed programs
DALLAS, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company building a portfolio of asset-focused subsidiaries to develop novel therapies for unmet medical needs, today reported its third quarter 2026 financial results and provided a corporate update.
Recent Highlights: * Asset-Focused Development Model: By combining focused and experienced teams with strategic support from Instil, Instil intends to establish a portfolio of asset-focused development subsidiaries. To accomplish this strategy, Instil intends to internally develop or in-license programs, building a diversified portfolio of development candidates. * Cash Position: Cash, cash equivalents, restricted cash, marketable securities and long-term investments totaled approximately $67.1 million as of September 30, 2026, which Instil expects will fund its current operating plan through 2027. Third Quarter 2026 Financial and Operating Results:
Get started
Create a free account to read the full story.
